Research Articles | Page 3 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Treatment of eculizumab refractory paroxysmal nocturnal hemoglobinuria: A systematic review about current treatment options and future direction Jun 2023 SAGE Open Medicine Paroxysmal Nocturnal Hemoglobinuria (PNH)
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists Dec 2023 Clinics in Laboratory Medicine Myelodysplastic Syndromes (MDS)
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care Jul 2023 Transplantation and Cellular Therapy Myelodysplastic Syndromes (MDS)
Transplant Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care Apr 2023 Transplantation and Cellular Therapy Myelodysplastic Syndromes (MDS)
Transfusion Support of Patients with Myelodysplastic Syndromes Dec 2023 Clinics in Laboratory Medicine Myelodysplastic Syndromes (MDS)
Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes Apr 2021 Hematology/oncology clinics of North America Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN)
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype Jul 2020 Blood Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Jan 2019 Leukemia Myelodysplastic Syndromes (MDS)
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes Jun 2023 Blood Advances Myelodysplastic Syndromes (MDS)
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS) May 2024 HemaSphere Myelodysplastic Syndromes (MDS)